Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates.

Viricel W, Fournet G, Beaumel S, Perrial E, Papot S, Dumontet C, Joseph B.

Chem Sci. 2019 Mar 6;10(14):4048-4053. doi: 10.1039/c9sc00285e. eCollection 2019 Apr 14.

2.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, Rodon P, Kolb B, Slama B, Mineur P, Voog E, Le Bris C, Fontan J, Maigre M, Beaumont M, Azais I, Sobol H, Vignon M, Royer B, Perrot A, Fuzibet JG, Dorvaux V, Anglaret B, Cony-Makhoul P, Berthou C, Desquesnes F, Pegourie B, Leyvraz S, Mosser L, Frenkiel N, Augeul-Meunier K, Leduc I, Leyronnas C, Voillat L, Casassus P, Mathiot C, Cheron N, Paubelle E, Moreau P, Bignon YJ, Joly B, Bourquard P, Caillot D, Naman H, Rigaudeau S, Marit G, Macro M, Lambrecht I, Cliquennois M, Vincent L, Helias P, Avet-Loiseau H, Moreno V, Reis RM, Varkonyi J, Kruszewski M, Vangsted AJ, Jurczyszyn A, Zaucha JM, Sainz J, Krawczyk-Kulis M, Wątek M, Pelosini M, Iskierka-Jażdżewska E, Grząśko N, Martinez-Lopez J, Jerez A, Campa D, Buda G, Lesueur F, Dudziński M, García-Sanz R, Nagler A, Rymko M, Jamroziak K, Butrym A, Canzian F, Obazee O, Nilsson B, Klein RJ, Lipkin SM, McKay JD, Dumontet C.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0452-6. [Epub ahead of print] No abstract available.

PMID:
30967618
3.

The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?

Dargaud Y, Fouassier M, Bordet JC, Ducastelle-Lepretre S, Dumontet C, Moreau P, Michallet M.

Leuk Lymphoma. 2019 Apr 3:1-4. doi: 10.1080/10428194.2019.1585839. [Epub ahead of print] No abstract available.

PMID:
30942646
4.

Lead optimization and biological evaluation of fragment-based cN-II inhibitors.

Guillon R, Rahimova R, Preeti, Egron D, Rouanet S, Dumontet C, Aghajari N, Jordheim LP, Chaloin L, Peyrottes S.

Eur J Med Chem. 2019 Apr 15;168:28-44. doi: 10.1016/j.ejmech.2019.02.040. Epub 2019 Feb 14.

PMID:
30798051
5.

In vitro modulation of multidrug resistance by pregnane steroids and in vivo inhibition of tumour development by 7α-OBz-11α(R)-OTHP-5β-pregnanedione in K562/R7 and H295R cell xenografts.

Alameh G, Emptoz-Bonneton A, Rolland de Ravel M, Matera EL, Mappus E, Balaguer P, Rocheblave L, Lomberget T, Dumontet C, Le Borgne M, Pugeat M, Grenot C, Cuilleron CY.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):684-691. doi: 10.1080/14756366.2019.1575825.

6.

Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).

Lehuédé C, Li X, Dauvillier S, Vaysse C, Franchet C, Clement E, Esteve D, Longué M, Chaltiel L, Le Gonidec S, Lazar I, Geneste A, Dumontet C, Valet P, Nieto L, Fallone F, Muller C.

Breast Cancer Res. 2019 Jan 17;21(1):7. doi: 10.1186/s13058-018-1088-6.

7.

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.

Campa D, Martino A, Macauda A, Dudziński M, Suska A, Druzd-Sitek A, Raab MS, Moreno V, Huhn S, Butrym A, Sainz J, Szombath G, Rymko M, Marques H, Lesueur F, Vangsted AJ, Vogel U, Kruszewski M, Subocz E, Buda G, Iskierka-Jażdżewska E, Ríos R, Merz M, Schöttker B, Mazur G, Perrial E, Martinez-Lopez J, Butterbach K, García Sanz R, Goldschmidt H, Brenner H, Jamroziak K, Reis RM, Kadar K, Dumontet C, Wątek M, Haastrup EK, Helbig G, Jurczyszyn A, Jerez A, Varkonyi J, Barington T, Grzasko N, Zaucha JM, Andersen V, Zawirska D, Canzian F.

Leuk Lymphoma. 2019 Jul;60(7):1803-1811. doi: 10.1080/10428194.2018.1551536. Epub 2019 Jan 11.

PMID:
30633655
8.

Engineering therapeutic bispecific antibodies using CrossMab technology.

Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P.

Methods. 2019 Feb 1;154:21-31. doi: 10.1016/j.ymeth.2018.11.008. Epub 2018 Nov 16. Review.

9.

The genomic landscape of plasma cells in systemic light chain amyloidosis.

Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, Johnson SK, Bauer MA, Weinhold N, Kaiser MF, Johnson DC, Jones JR, Pawlyn C, Proszek P, Schinke C, Facon T, Dumontet C, Davies FE, Morgan GJ, Walker BA, Wechalekar AD.

Blood. 2018 Dec 27;132(26):2775-2777. doi: 10.1182/blood-2018-08-872226. Epub 2018 Nov 16. No abstract available.

PMID:
30446495
10.

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.

Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, Serre L, Jordheim LP, Matera EL, Dumontet C.

Front Immunol. 2018 Oct 9;9:2100. doi: 10.3389/fimmu.2018.02100. eCollection 2018.

11.

Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length.

Sut C, Hamzeh-Cognasse H, Arthaud CA, Eyraud MA, Chettab K, Dumontet C, Laradi S, Burnouf T, Garraud O, Cognasse F.

Transfusion. 2018 Nov;58(11):2635-2644. doi: 10.1111/trf.14973. Epub 2018 Oct 16.

PMID:
30325037
12.

Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.

Dumontet C, Beck G, Gardebien F, Haudecoeur R, Mathé D, Matera EL, Tourette A, Mattei E, Esmenjaud J, Boyère C, Nurisso A, Peuchmaur M, Pérès B, Bouchaud G, Magnan A, Monneret G, Boumendjel A.

Eur J Med Chem. 2018 Oct 5;158:405-413. doi: 10.1016/j.ejmech.2018.09.033. Epub 2018 Sep 12.

PMID:
30237123
13.

CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates.

Dumontet C, Peyrottes S, Rabeson C, Cros-Perrial E, Géant PY, Chaloin L, Jordheim LP.

Eur J Med Chem. 2018 Sep 5;157:1051-1055. doi: 10.1016/j.ejmech.2018.08.035. Epub 2018 Aug 17.

PMID:
30176535
14.

Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells.

Jordheim LP, Chettab K, Cros-Perrial E, Matera EL, Dumontet C.

Pharmacology. 2018;102(3-4):161-168. doi: 10.1159/000491587. Epub 2018 Jul 26.

PMID:
30048976
15.

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T.

Leukemia. 2018 Jun;32(6):1404-1413. doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26.

16.

Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway.

Sauveur J, Matera EL, Chettab K, Valet P, Guitton J, Savina A, Dumontet C.

Oncotarget. 2018 Apr 20;9(30):21141-21155. doi: 10.18632/oncotarget.24975. eCollection 2018 Apr 20.

17.

Real life management of patients hospitalized with multiple myeloma in France.

Dumontet C, Couray-Targe S, Teisseire M, Karlin L, Maucort-Boulch D.

PLoS One. 2018 May 1;13(5):e0196596. doi: 10.1371/journal.pone.0196596. eCollection 2018.

18.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM.

Cancer Res. 2018 May 15;78(10):2747-2759. doi: 10.1158/0008-5472.CAN-17-1900. Epub 2018 Mar 20.

19.

Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk.

Waller RG, Darlington TM, Wei X, Madsen MJ, Thomas A, Curtin K, Coon H, Rajamanickam V, Musinsky J, Jayabalan D, Atanackovic D, Rajkumar SV, Kumar S, Slager S, Middha M, Galia P, Demangel D, Salama M, Joseph V, McKay J, Offit K, Klein RJ, Lipkin SM, Dumontet C, Vachon CM, Camp NJ.

PLoS Genet. 2018 Feb 1;14(2):e1007111. doi: 10.1371/journal.pgen.1007111. eCollection 2018 Feb.

20.

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia.

Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, Tigaud I, Pages MP, Chelghoum Y, Baracco F, Labussierre H, Ducastelle S, Paubelle E, Nicolini FE, Elhamri M, Campos L, Plesa C, Morisset S, Salles G, Bertrand Y, Michallet M, Thomas X.

World J Stem Cells. 2017 Dec 26;9(12):227-234. doi: 10.4252/wjsc.v9.i12.227.

21.

Granulocyte-Colony Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part II): Dose-Dependent Biodistribution and In Vivo Antitumor Efficacy in Combination with Rituximab.

Kryza D, De Crozals G, Mathe D, Taleb Sidi-Boumedine J, Janier M, Chaix C, Dumontet C.

Bioconjug Chem. 2018 Mar 21;29(3):804-812. doi: 10.1021/acs.bioconjchem.7b00606. Epub 2018 Jan 17.

PMID:
29283559
22.

Granulocyte Colony-Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part I): Synthesis and Biodistribution Studies.

De Crozals G, Kryza D, Sánchez GJ, Roux S, Mathé D, Taleb J, Dumontet C, Janier M, Chaix C.

Bioconjug Chem. 2018 Mar 21;29(3):795-803. doi: 10.1021/acs.bioconjchem.7b00605. Epub 2018 Jan 17.

PMID:
29283548
23.

Functions of the multi-interacting protein KIDINS220/ARMS in cancer and other pathologies.

Raza MZ, Allegrini S, Dumontet C, Jordheim LP.

Genes Chromosomes Cancer. 2018 Mar;57(3):114-122. doi: 10.1002/gcc.22514. Epub 2017 Dec 20. Review.

PMID:
29181864
24.

Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding.

Hirz T, Matera EL, Chettab K, Jordheim LP, Mathé D, Evesque A, Esmenjaud J, Salles G, Dumontet C.

Oncotarget. 2017 Aug 18;8(42):72818-72834. doi: 10.18632/oncotarget.20350. eCollection 2017 Sep 22.

25.

The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells.

Bricard G, Cadassou O, Cassagnes LE, Cros-Perrial E, Payen-Gay L, Puy JY, Lefebvre-Tournier I, Tozzi MG, Dumontet C, Jordheim LP.

Oncotarget. 2017 Jun 27;8(40):67380-67393. doi: 10.18632/oncotarget.18653. eCollection 2017 Sep 15.

26.

The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance.

Duong MN, Geneste A, Fallone F, Li X, Dumontet C, Muller C.

Oncotarget. 2017 May 20;8(34):57622-57641. doi: 10.18632/oncotarget.18038. eCollection 2017 Aug 22. Review.

27.

Modeling the Colchicum autumnale Tubulin and a Comparison of Its Interaction with Colchicine to Human Tubulin.

Spasevska I, Ayoub AT, Winter P, Preto J, Wong GK, Dumontet C, Tuszynski JA.

Int J Mol Sci. 2017 Aug 2;18(8). pii: E1676. doi: 10.3390/ijms18081676.

28.

Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.

Boespflug A, Funck-Brentano E, Hélias-Rodzewicz Z, Maucort-Boulch D, Beauchet A, Bringuier PP, Dumontet C, Emile JF, Saiag P, Dalle S.

Pigment Cell Melanoma Res. 2017 Sep;30(5):498-500. doi: 10.1111/pcmr.12606. Epub 2017 Jul 23. No abstract available.

PMID:
28627072
29.

Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells.

Puy JY, Jordheim LP, Cros-Perrial E, Dumontet C, Peyrottes S, Lefebvre-Tournier I.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 15;1053:101-110. doi: 10.1016/j.jchromb.2017.03.024. Epub 2017 Mar 24.

PMID:
28415014
30.

Strategies and challenges for the next generation of antibody-drug conjugates.

Beck A, Goetsch L, Dumontet C, Corvaïa N.

Nat Rev Drug Discov. 2017 May;16(5):315-337. doi: 10.1038/nrd.2016.268. Epub 2017 Mar 17. Review.

PMID:
28303026
31.

Monoclonal antibody therapy in multiple myeloma.

Touzeau C, Moreau P, Dumontet C.

Leukemia. 2017 May;31(5):1039-1047. doi: 10.1038/leu.2017.60. Epub 2017 Feb 17. Review.

PMID:
28210004
32.

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E.

Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16.

PMID:
28167452
33.

Doxorubicin Delivery into Tumor Cells by Stable Cavitation without Contrast Agents.

Chettab K, Mestas JL, Lafond M, Saadna DE, Lafon C, Dumontet C.

Mol Pharm. 2017 Feb 6;14(2):441-447. doi: 10.1021/acs.molpharmaceut.6b00880. Epub 2017 Jan 20.

PMID:
28107023
34.

Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients.

Marcel V, Catez F, Berger CM, Perrial E, Plesa A, Thomas X, Mattei E, Hayette S, Saintigny P, Bouvet P, Diaz JJ, Dumontet C.

PLoS One. 2017 Jan 19;12(1):e0170160. doi: 10.1371/journal.pone.0170160. eCollection 2017.

35.

Stably transfected adherent cancer cell models with decreased expression of 5'-nucleotidase cN-II.

Bricard G, Cros-Perrial E, Machon C, Dumontet C, Jordheim LP.

Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):604-612.

PMID:
27906612
36.

Deoxycholic acid derivatives as inhibitors of P-glycoprotein-mediated multidrug efflux.

Rocheblave L, de Ravel MR, Monniot E, Tavenard J, Cuilleron CY, Grenot C, Radix S, Matera EL, Dumontet C, Walchshofer N.

Steroids. 2016 Dec;116:5-12. doi: 10.1016/j.steroids.2016.09.017. Epub 2016 Sep 30.

PMID:
27697501
37.

Identification of miRSNPs associated with the risk of multiple myeloma.

Macauda A, Calvetti D, Maccari G, Hemminki K, Försti A, Goldschmidt H, Weinhold N, Houlston R, Andersen V, Vogel U, Buda G, Varkonyi J, Sureda A, Martinez Lopez J, Watek M, Butrym A, Sarasquete ME, Dudziński M, Jurczyszyn A, Druzd-Sitek A, Kruszewski M, Subocz E, Petrini M, Iskierka-Jażdżewska E, Raźny M, Szombath G, Marques H, Zawirska D, Chraniuk D, Halka J, Hove Jacobsen SE, Mazur G, García Sanz R, Dumontet C, Moreno V, Stępień A, Beider K, Pelosini M, Manuel Reis R, Krawczyk-Kulis M, Rymko M, Avet-Loiseau H, Lesueur F, Grząśko N, Ostrovsky O, Jamroziak K, Vangsted AJ, Jerez A, Tomczak W, Zaucha JM, Kadar K, Sainz J, Nagler A, Landi S, Gemignani F, Canzian F.

Int J Cancer. 2017 Feb 1;140(3):526-534. doi: 10.1002/ijc.30465. Epub 2016 Nov 9.

38.

Beta-hydroxyphosphonate ribonucleoside analogues derived from 4-substituted-1,2,3-triazoles as IMP/GMP mimics: synthesis and biological evaluation.

Nguyen Van T, Hospital A, Lionne C, Jordheim LP, Dumontet C, Périgaud C, Chaloin L, Peyrottes S.

Beilstein J Org Chem. 2016 Jul 18;12:1476-86. doi: 10.3762/bjoc.12.144. eCollection 2016.

39.

A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.

Ríos-Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, Landi S, Jamroziak K, Dumontet C, Wątek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, Vogel U, Buda G, García-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Försti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J.

Oncotarget. 2016 Sep 13;7(37):59029-59048. doi: 10.18632/oncotarget.10665.

40.

A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells.

Broussas M, Boute N, Akla B, Berger S, Beau-Larvor C, Champion T, Robert A, Beck A, Haeuw JF, Goetsch L, Bailly C, Dumontet C, Matthes T, Corvaia N, Klinguer-Hamour C.

Mol Cancer Ther. 2016 Aug;15(8):1890-9. doi: 10.1158/1535-7163.MCT-16-0041. Epub 2016 Jun 13.

41.
42.

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.

Magrangeas F, Kuiper R, Avet-Loiseau H, Gouraud W, Guérin-Charbonnel C, Ferrer L, Aussem A, Elghazel H, Suhard J, Sakissian H, Attal M, C Munshi N, Sonneveld P, Dumontet C, Moreau P, van Duin M, Campion L, Minvielle S.

Clin Cancer Res. 2016 Sep 1;22(17):4350-4355. doi: 10.1158/1078-0432.CCR-15-3163. Epub 2016 Apr 8.

43.

Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies.

Cornet S, Mathé D, Chettab K, Evesque A, Matera EL, Trédan O, Dumontet C.

Mol Cancer Ther. 2016 Jun;15(6):1238-47. doi: 10.1158/1535-7163.MCT-15-0759. Epub 2016 Mar 17.

44.

Alteration of Natural Killer cell phenotype and function in obese individuals.

Viel S, Besson L, Charrier E, Marçais A, Disse E, Bienvenu J, Walzer T, Dumontet C.

Clin Immunol. 2017 Apr;177:12-17. doi: 10.1016/j.clim.2016.01.007. Epub 2016 Jan 18.

PMID:
26794911
45.

Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.

Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudziński M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Juul Vangsted A, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C.

Nat Commun. 2015 Dec 9;6:10203. doi: 10.1038/ncomms10203. No abstract available.

46.

The druggability of intracellular nucleotide-degrading enzymes.

Rampazzo C, Tozzi MG, Dumontet C, Jordheim LP.

Cancer Chemother Pharmacol. 2016 May;77(5):883-93. doi: 10.1007/s00280-015-2921-6. Epub 2015 Nov 27. Review.

PMID:
26614508
47.

Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach.

Marton Z, Guillon R, Krimm I, Preeti, Rahimova R, Egron D, Jordheim LP, Aghajari N, Dumontet C, Périgaud C, Lionne C, Peyrottes S, Chaloin L.

J Med Chem. 2015 Dec 24;58(24):9680-96. doi: 10.1021/acs.jmedchem.5b01616. Epub 2015 Dec 7.

PMID:
26599519
48.

Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization.

Pertesi M, Galia P, Nazaret N, Vallée M, Garderet L, Leleu X, Avet-Loiseau H, Foll M, Byrnes G, Lachuer J, McKay JD, Dumontet C.

PLoS One. 2015 Sep 9;10(9):e0136505. doi: 10.1371/journal.pone.0136505. eCollection 2015.

49.

Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).

Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Michallet M, Thomas X, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F.

Oncotarget. 2016 Jan 19;7(3):2889-909. doi: 10.18632/oncotarget.3898.

50.

Spatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast Agents.

Chettab K, Roux S, Mathé D, Cros-Perrial E, Lafond M, Lafon C, Dumontet C, Mestas JL.

PLoS One. 2015 Aug 14;10(8):e0134247. doi: 10.1371/journal.pone.0134247. eCollection 2015.

Supplemental Content

Loading ...
Support Center